Malate salt of N-(4-{ [ 6, 7-bis (methyloxy)-quinolin-4-yl] oxy}phenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer

Details for Australian Patent Application No. 2010204619 (hide)

International Classifications

Event Publications

1 September 2011 PCT application entered the National Phase

PCT publication WO2010/083414 Priority application(s): WO2010/083414

27 October 2011 Amendment Made

The nature of the amendment is: Amend the invention title to read Malate salt of N-(4-{ [ 6, 7-bis (methyloxy)-quinolin-4-yl] oxy}phenyl)-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer

3 November 2011 Alteration of Name

The name of the applicant has been altered to Bristol-Myers Squibb Company; Exelixis, Inc.

19 January 2012 Assignment before Grant

Exelixis, Inc.; Bristol-Myers Squibb Company The application has been assigned to Exelixis, Inc.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.